Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial

INTRODUCTION: The clinical characteristics of autoantibody-mediated autoimmune diseases are diverse. Yet, medical treatment and the associated complications are similar, that is, the occurrence of long-term side effects and the problem that a significant proportion of patients are non-responders. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohler, Siegfried, Märschenz, Stefanie, Grittner, Ulrike, Alexander, Tobias, Hiepe, Falk, Meisel, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352837/
https://www.ncbi.nlm.nih.gov/pubmed/30696682
http://dx.doi.org/10.1136/bmjopen-2018-024523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352837/
https://www.ncbi.nlm.nih.gov/pubmed/30696682
http://dx.doi.org/10.1136/bmjopen-2018-024523

Ejemplares similares